Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors

MLA

Adam D. Durbin, et al. “Mechanisms Underlying Synergy between DNA Topoisomerase I-Targeted Drugs and MTOR Kinase Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.” Oncogene, vol. 38, no. 39, Nov. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....66e9c9a848e9ab0ccb0249760a64261f&authtype=sso&custid=ns315887.

APA

Adam D. Durbin, A. Thomas Look, Dong Hyuk Ki, & Felix Oppel. (2018). Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene, 38(39).

Chicago

Adam D. Durbin, A. Thomas Look, Dong Hyuk Ki, and Felix Oppel. 2018. “Mechanisms Underlying Synergy between DNA Topoisomerase I-Targeted Drugs and MTOR Kinase Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.” Oncogene 38 (39). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....66e9c9a848e9ab0ccb0249760a64261f&authtype=sso&custid=ns315887.